TWI302457B - A pharmaceutical composition for improving blood lipid or reducing blood homocysteine - Google Patents

A pharmaceutical composition for improving blood lipid or reducing blood homocysteine Download PDF

Info

Publication number
TWI302457B
TWI302457B TW092118805A TW92118805A TWI302457B TW I302457 B TWI302457 B TW I302457B TW 092118805 A TW092118805 A TW 092118805A TW 92118805 A TW92118805 A TW 92118805A TW I302457 B TWI302457 B TW I302457B
Authority
TW
Taiwan
Prior art keywords
blood
salt
hmg
homocysteine
pharmaceutical composition
Prior art date
Application number
TW092118805A
Other languages
English (en)
Chinese (zh)
Other versions
TW200403053A (en
Inventor
Kondo Tatsuhito
Takagi Ikuo
Nakayama Masato
Torizumi Yasuhiro
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200403053A publication Critical patent/TW200403053A/zh
Application granted granted Critical
Publication of TWI302457B publication Critical patent/TWI302457B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW092118805A 2002-07-11 2003-07-10 A pharmaceutical composition for improving blood lipid or reducing blood homocysteine TWI302457B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002202121 2002-07-11
JP2002343586 2002-11-27

Publications (2)

Publication Number Publication Date
TW200403053A TW200403053A (en) 2004-03-01
TWI302457B true TWI302457B (en) 2008-11-01

Family

ID=30117429

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092118805A TWI302457B (en) 2002-07-11 2003-07-10 A pharmaceutical composition for improving blood lipid or reducing blood homocysteine

Country Status (7)

Country Link
JP (1) JP2010077162A (fr)
CN (1) CN100341509C (fr)
AU (1) AU2003281176A1 (fr)
CA (1) CA2492781A1 (fr)
HK (1) HK1077232A1 (fr)
TW (1) TWI302457B (fr)
WO (1) WO2004006919A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060975A1 (fr) * 2003-12-23 2005-07-07 Medicure International Inc. Polytherapies mettant en oeuvre une composition renfermant un inhibiteur de l'hmg coa reductase et un compose relatif a la vitamine b6
TW200612896A (en) * 2004-09-21 2006-05-01 Sankyo Co Pharmaceutical compositions containing with HMG-CoA reductase inhibitor and glutathione
JP4949661B2 (ja) * 2004-09-21 2012-06-13 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
US9597289B2 (en) * 2006-04-26 2017-03-21 Rosemont Pharmaceuticals Ltd. Liquid oral simvastatin compositions
JPWO2015060317A1 (ja) * 2013-10-22 2017-04-06 長谷川　亨 神経変性疾患の検査方法
JP6009050B1 (ja) * 2015-08-21 2016-10-19 国立大学法人東北大学 飲酒による悪酔いまたは二日酔いの軽減または予防剤
WO2020046132A1 (fr) 2018-08-31 2020-03-05 Leiden University Chaperons pharmacologiques pour une thérapie par traitement enzymatique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105177A1 (fr) * 1992-09-14 1994-03-15 Willem Jacob Serfontein Preparations pharmaceutiques pour la reduction des taux d'homocysteine
AU732465B2 (en) * 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
CA2306646A1 (fr) * 1997-10-22 1999-04-29 Merck & Co., Inc. Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
AU3651102A (en) * 2000-11-29 2002-06-11 Smithkline Beecham Corp Composition containing statins and calcium for improved cardiovascular health
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
TW200403053A (en) 2004-03-01
CN1681499A (zh) 2005-10-12
CN100341509C (zh) 2007-10-10
HK1077232A1 (en) 2006-02-10
CA2492781A1 (fr) 2004-01-22
WO2004006919A1 (fr) 2004-01-22
AU2003281176A1 (en) 2004-02-02
JP2010077162A (ja) 2010-04-08

Similar Documents

Publication Publication Date Title
CA1165689A (fr) Methode pour augmenter l'absorption orale d'agents bioactifs polaires
US20120014907A1 (en) Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
TWI393560B (zh) 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20050187204A1 (en) Medicinal composition for lowering blood lipid level
JP2001514224A (ja) アムロジピンとスタチン化合物を含む併用療法
JP2010077162A (ja) 血中ホモシステイン低下のための医薬組成物
JP2007530688A (ja) 肝毒性が減少した組成物
JP5362151B2 (ja) Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
TWI284529B (en) A composition for lowering triglyceride
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
JP2008189684A (ja) 血中脂質改善剤組成物
CA2534910C (fr) Compositions pharmaceutiques stables a liberation controlee contenant du fenofibrate et de la pravastatine
JP2003503342A (ja) ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用
US20080070938A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
JP2023530452A (ja) バダデュスタットの薬物間相互作用の調節
JP4607436B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
JP4454985B2 (ja) 血液脂質を低下させるための医薬組成物
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
JP4611622B2 (ja) 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
CA2494916A1 (fr) Composition medicale abaissant le taux de lipides sanguins
JP4132773B2 (ja) 血中脂質改善剤組成物
CA2494801A1 (fr) Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase
JP4248780B2 (ja) 過酸化脂質低下剤組成物
JP4212271B2 (ja) 血中脂質改善剤組成物
CN100415235C (zh) 含有HMG-CoA还原酶抑制剂的药物组合物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees